RxDoctor Payments Data

Rory Sears, DO

Pulmonary Disease · Watertown, NYNPI 1891997136

Payments from drug & device makers

$5,800in general payments, 2019–2025

Across 46 payments — averaging $126.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Medical Device Business Services, Inc.$877
  • AstraZeneca$149
  • Boehringer Ingelheim$125
  • GSK$97
  • Regeneron Healthcare Solutions, Inc.$85
  • plus $353 from 12 others

What the payments were for

  • Speaking & faculty fees$3,80066%
  • Travel & lodging$92216%
  • Food & beverage$1,06118%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,800 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$55,303
Medicare patients
272
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter267$273,751
XolairOmalizumab59$142,177
Breztri AerosphereBudesonide/Glycopyr/Formoterol172$138,157
Breo ElliptaFluticasone/Vilanterol247$134,765
Spiriva RespimatTiotropium Bromide121$105,759
Dupixent SyringeDupilumab23$94,115
Incruse ElliptaUmeclidinium Bromide147$78,219
TezspireTezepelumab-Ekko18$77,860
Dupixent PenDupilumab13$48,647
Advair HfaFluticasone Propion/Salmeterol67$43,688
SymbicortBudesonide/Formoterol Fumarate100$41,998
Arnuity ElliptaFluticasone Furoate87$36,192
Fluticasone-SalmeterolFluticasone Propion/Salmeterol159$35,128
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$31,810
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$26,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta$97$549,163791 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$149$258,015290 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$125$159,342178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →